December 20, 2018  |  Announcements  |  By  |  0 Comments

Our CEO’s Top Observations from ASH 2018

headshot_dave800pxAsh-Image-6

This month, we were pleased to exhibit at the annual meeting for the American Society for Hematology (ASH), the most comprehensive hematology event of the year. We were excited to witness firsthand the rapid development of immunotherapy and the use of cutting-edge technologies (including Cytobank) being used by leaders in hematology from around the world.

The main trends I observed at ASH relevant to the research we support were:

  • The continued growth in high-dimensional cytometry in the clinical research setting, especially CyTOF
  • The increase in utilization of machine learning algorithms for cytometry and single cell RNA data, especially tSNE (viSNE)
  • The growing use of scRNA-seq and cytometry in a complementary manner in the same studies.  

In addition, there were a number of presentations and posters that featured machine learning visualizations, many of them generated on the Cytobank platform. See below for some terrific examples.

New Demands for High Dimensional Methods
Among the clinicians and scientists we encountered, many are migrating to a high-dimensional approach for a variety of reasons. Low-dimensional methods cannot capture the immense heterogeneity of the tumor microenvironment. Also, identification of improved biomarkers benefits from deep phenotypic analysis of different immune cell compartments simultaneously, which isn’t feasible with lower dimensional cytometry.

Lastly, the availability of fast, high-capacity, and user-friendly computing platforms (like Cytobank) has made it possible for more scientists to analyze high-dimensional single cell data.

FlowSOM Now Available in Cytobank
Cytobank users I spoke with were excited about the recent addition of
FlowSOM on Cytobank. Many noted that gaining access to scalable cloud compute would enable them to perform much larger analyses than they currently do, and that it’s now more convenient to use with it linked to the other analysis tools on the Cytobank.  We now have a video tutorial taking you step by step through the FlowSOM workflow, and will follow with other use cases in the the coming weeks.


We were delighted to see so many of our Cytobank customers and collaborators who were chosen to present at the meeting. Check out a sampling of them here:

The Mayo Clinic’s Dr. Tax Kourelis with his poster #1879: “Mass Cytometry Identifies Immunomic Shifts in the Bone Marrow Microenvironment of Multiple Myeloma and Light Chain Amyloidosis after Standard of Care First Line Therapies”
The Mayo Clinic’s Dr. Tax Kourelis with his poster #1879: “Mass Cytometry Identifies Immunomic Shifts in the Bone Marrow Microenvironment of Multiple Myeloma and Light Chain Amyloidosis after Standard of Care First Line Therapies”

 

Deborah Czerwinski from Stanford’s Levy Lab presentes Poster #1612: “Intratumoral Injection of CpG-ODN Plus Systemic Ibrutinib Induces an Anti-Tumor Immune Response Affecting T Cell Subsets in the Microenvironment of Both Injected and Non-Injected Tumor Sites in Patients with Low-Grade Lymphoma.”
Deborah Czerwinski from The Levy Lab at Stanford Presents Poster #1612: “Intratumoral Injection of CpG-ODN Plus Systemic Ibrutinib Induces an Anti-Tumor Immune Response Affecting T Cell Subsets in the Microenvironment of Both Injected and Non-Injected Tumor Sites in Patients with Low-Grade Lymphoma.”

 

1502-Tislevoll-BergenU-ASH18-1200px
Dr. Benedicte Sjo Tisvoll of the University of Bergen presents Poster #1502: “A 36-Dimensional Cytometry by Time of Flight (CyTOF) Analysis of De Novo Acute Myeloid Leukemia (AML) Patients Eligible for Intensive Chemotherapy”

 

Dr.Edward Truelove of Barts Cancer Institute, Queen Mary University London discusses Poster #2863: Deep Phenotypic Analysis Reveals a Monocyte Subpopulation Predictive of Relapse/Refractory Diffuse Large B-Cell Lymphoma
Dr. Edward Truelove of Barts Cancer Institute, Queen Mary University London discusses Poster #2863: Deep Phenotypic Analysis Reveals a Monocyte Subpopulation Predictive of Relapse/Refractory Diffuse Large B-Cell Lymphoma

 

Dr. Stephen Oh of WUSTL presents Poster #3062: “Aberrant Cytokine Production in Myelofibrosis Is Not Rectified By Ruxolitinib and Is Differentially Sensitive to Inhibition of JAK/STAT, MAP Kinase, and NFkB Signaling.”
Dr. Stephen Oh of Washington University, St. Louis presents Poster #3062: “Aberrant Cytokine Production in Myelofibrosis Is Not Rectified By Ruxolitinib and Is Differentially Sensitive to Inhibition of JAK/STAT, MAP Kinase, and NFkB Signaling.”

 

Dana-Farber’s Dr. Tomohiro Kubo in Oral Presentation #606: "Low-Dose Interleukin-2 Therapy Enhances Cytotoxicity of CD56bright NK Cells in Patients with Chronic GvHD."
Dana-Farber’s Dr. Tomohiro Kubo in Oral Presentation #606: “Low-Dose Interleukin-2 Therapy Enhances Cytotoxicity of CD56bright NK Cells in Patients with Chronic GvHD.”

 

Dr. Todd Fehniger of Washington University, St. Louis Oral Presentation: "SCI-8 Memory-Like Natural Killer Cells" Here, he discusses the biology of NK cells, provides an overview of innate memory-like responses by NK cells, and use of these cells in early-phase clinical trials as a form of cellular adoptive immunotherapy for leukemia patients. Extensive utilization of high dimensional immunology featuring CyTOF and SPADE, viSNE and CITRUS on Cytobank.
Dr. Todd Fehniger of Washington University, St. Louis in Oral Presentation #SCI-8: “Memory-Like Natural Killer Cells” Here, he discusses the biology of NK cells, provides an overview of innate memory-like responses by NK cells, and use of these cells in early-phase clinical trials as a form of cellular adoptive immunotherapy for leukemia patients. Extensive utilization of high dimensional immunology featuring CyTOF and SPADE, viSNE and CITRUS on Cytobank.

 

Dr.Robert Schreiber of Washington University, St. Louis Oral Presentation #SCI-17: "Neoepitope Discovery" Here he discusses using RNAseq and CYTOF analyzed by Cytobank to discover complex changes within the myeloid compartment that prove new insights into the mechanism of action of immune checkpoint blockade therapy.
Dr.Robert Schreiber of Washington University, St. Louis Oral Presentation #SCI-17: “Neoepitope Discovery”
Here he discusses using RNAseq and CYTOF analyzed by Cytobank to discover complex changes within the myeloid compartment that prove new insights into the mechanism of action of immune checkpoint blockade therapy.